



NEWS RELEASE

For Further Information Contact:

Roy Wolvin

Nymox Pharmaceutical Corporation

800-93NYMOX

www.nymox.com

For Immediate Release:

Nymox Announces Dosing of First Patient in Phase 3 Trial for NX-1207 for BPH

Hasbrouck Heights, NJ (June 2, 2009) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced the dosing of the first patient in the Company's NX02-0017 multi-center, double-blind, placebo controlled Phase 3 U.S. clinical trial for NX-1207, the Company's investigational drug for the treatment of benign prostatic hyperplasia (BPH).

NX-1207 involves a new targeted approach to the treatment of BPH. The drug is administered by a urologist in an office setting by injection directly into the zone of the prostate where the enlargement occurs. The procedure takes only a few minutes, does not require anaesthesia or catheterization and causes little or no pain or discomfort. In multicenter U.S. clinical trials to date, NX-1207 has been found to produce improvements in BPH symptoms that are approximately double that reported for currently approved BPH drugs. Patients treated with NX-1207 have thus far not had sexual and blood pressure and other side effects that are associated with currently approved BPH drugs. Follow-up studies of available subjects from controlled NX-1207 clinical trials have provided evidence of durable benefits from NX-1207 treatment for up to 5 years from the date of treatment.

Urology clinical research centers across the U.S. are participating in the Phase 3 trials of NX-1207. A total enrollment of 1000 men will be involved in the 2 NX-1207 Phase 3 clinical trials, NX02-0017 and NX02-0018. To date, investigative site recruitment and enrolment activities are proceeding well. In addition, many men across the country have already contacted the sites and the Company to express interest in participation in the NX-1207 clinical trials.

BPH is one of the most commonly diagnosed diseases in the U.S. adult male population. Up to 46% of men between the ages of 40 and 79 suffer from moderate to severe urinary problems and symptoms associated with BPH. The condition can seriously impact health and quality of life and can lead to urinary retention, incontinence, and other serious consequences.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

###